TY - JOUR
T1 - Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis
AU - Carrillo, E.
AU - Ahmed, S.
AU - Goldsmith-Pestana, K.
AU - Nieto, J.
AU - Osorio, Y.
AU - Travi, B.
AU - Moreno, J.
AU - McMahon-Pratt, D.
N1 - Funding Information:
This work was supported by the Ministerio de Ciencia y Tecnologia grant AGL 2000-0284 and a Grant from the NIH (AI27811). E. Carrillo was supported by a FPI fellowship from the Ministerio de Ciencia y Tecnologia. S. Ahmed was supported by fellowships from the Howard Hughes Medical Institute and Yale Downs International Health Fellowship. J. Moreno holds a “Ramon y Cajal” contract from MEC.
PY - 2007/2/9
Y1 - 2007/2/9
N2 - The P-8 proteoglycolipid complex (P-8 PGLC), an amastigote antigen of Leishmania pifanoi, has been demonstrated to induce protection in mouse models, as well as to induce Tc1/Th1-like cellular responses in American cutaneous leishmaniasis patients. Because the immunization with P-8 PGLC in the murine model does not appear to be genetically restricted, we have studied the reactivity of the P-8 PGLC in Leishmania infantum infected dogs. In this study, it is shown that PBMC from experimentally infected dogs (asymptomatic, oligosymptomatic) significantly proliferated in response to soluble leishmanial antigen (SLA) or the P-8 PGLC. Further, quantification of the gene expression induced by the stimulation with P-8 in asymptomatically infected dogs showed an up-regulation of IFN-γ and TNF-α, which were three to 4-fold higher than that induced by soluble Leishmania antigen (SLA). While no measurable induction of IL-10 was observed, low levels of IL-4 mRNA were observed in response to both P-8 and SLA antigens. Thus, our studies establish that P-8 is recognized by infected canines and elicits a potentially curative/protective Th1-like immune response. The identification of Leishmania antigens that elicit appropriate immune responses across different host species (humans, canine) and disease manifestations (cutaneous or visceral) could be an advantage in generating a general vaccine for leishmaniasis.
AB - The P-8 proteoglycolipid complex (P-8 PGLC), an amastigote antigen of Leishmania pifanoi, has been demonstrated to induce protection in mouse models, as well as to induce Tc1/Th1-like cellular responses in American cutaneous leishmaniasis patients. Because the immunization with P-8 PGLC in the murine model does not appear to be genetically restricted, we have studied the reactivity of the P-8 PGLC in Leishmania infantum infected dogs. In this study, it is shown that PBMC from experimentally infected dogs (asymptomatic, oligosymptomatic) significantly proliferated in response to soluble leishmanial antigen (SLA) or the P-8 PGLC. Further, quantification of the gene expression induced by the stimulation with P-8 in asymptomatically infected dogs showed an up-regulation of IFN-γ and TNF-α, which were three to 4-fold higher than that induced by soluble Leishmania antigen (SLA). While no measurable induction of IL-10 was observed, low levels of IL-4 mRNA were observed in response to both P-8 and SLA antigens. Thus, our studies establish that P-8 is recognized by infected canines and elicits a potentially curative/protective Th1-like immune response. The identification of Leishmania antigens that elicit appropriate immune responses across different host species (humans, canine) and disease manifestations (cutaneous or visceral) could be an advantage in generating a general vaccine for leishmaniasis.
KW - Canine
KW - Cytokine
KW - Immunogenicity
KW - Leishmania
KW - P-8
UR - http://www.scopus.com/inward/record.url?scp=33846115054&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846115054&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2006.10.036
DO - 10.1016/j.vaccine.2006.10.036
M3 - Article
C2 - 17178178
AN - SCOPUS:33846115054
SN - 0264-410X
VL - 25
SP - 1534
EP - 1543
JO - Vaccine
JF - Vaccine
IS - 8
ER -